Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy.

ABSTRACT:

Background

Randomized clinical trials support deescalation of axillary surgery in breast cancer patients with low-volume axillary disease treated with a surgery-first approach. However, few data exist to guide axillary surgery following neoadjuvant endocrine therapy (NET). Therefore, we evaluated the extent and outcomes of axillary surgery in a contemporary cohort of NET patients, a treatment approach that has become particularly relevant during the coronavirus disease-19 (COVID-19) pandemic.

Patients and methods

We identified invasive breast cancer patients treated with NET between October 2008 and November 2019. Patients presenting with stage IV disease or recurrent disease were excluded. Statistical analyses were performed using chi-square, Fisher's exact, and Wilcoxon ra

SUBMITTER: Murphy BM 

PROVIDER: S-EPMC8286162 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature